The DOI matches its Crossref record; 288 of the 288 references it cites were found in a registry or an index.
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Open accessAbstract
In tumors, Cancer-Associated Fibroblasts (CAFs) constitute the most prominent component of the tumor microenvironment (TME). CAFs are heterogeneous and composed of different CAF subsets exerting distinct functions in tumors. Specific CAF subpopulations actively influence various aspects of tumor growth, including cancer cell survival and proliferation, angiogenesis, extracellular matrix (ECM) remodeling, metastatic spread and chemoresistance. During the past decade, some CAF subsets have also been shown to modulate anti-tumor immune response. Indeed, they can increase the content in regulatory T lymphocytes and inhibit the activity of effector and cytotoxic immune cells. These functions are mainly controlled by their constitutive secretion of cytokines, chemokines, growth factors and ECM proteins, either directly in the surrounding extracellular space or through micro-vesicles. Some CAFs also express key regulators of immune checkpoints. The different roles played by CAFs, both as immunosuppressor or as physical support for tumor cell progression, set them as promising targets for anti-tumor therapies. In this review, we describe the main current knowledge on CAFs heterogeneity and immunosuppressive microenvironment, as well as their potential therapeutic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wang, J., Ying, G., Wang, J., Jung, Y., Lu, J., Zhu, J., Pienta, K. J., & Taichman, R. S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2863 · Cited by 96
RetractedMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
The biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Myofibroblasts and mechano-regulation of connective tissue remodelling
Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C., & Brown, R. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm809 · Cited by 4,290
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863 · cited 3×
“TME components are central to all stages of tumorigenesis and metastasis [1-4].”
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Cano, A., Pérez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., Portillo, F., & Nieto, M. A. (2000) · Nature Cell Biology · doi:10.1038/35000025 · Cited by 3,668
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110
The extracellular matrix: A dynamic niche in cancer progression
Lu, P., Weaver, V. M., & Werb, Z. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201102147 · Cited by 3,024 · cited 1×
“Increased ECM rigidity resulting from thickening of collagen fibers provides cues favoring migration, attachment, survival and proliferation of cancer cells [229].”
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681 · cited 3×
“Indeed, several CAF subpopulations have been identified and have either tumor-promoting [25, 27, 31-36] or tumor-suppressive effects [37, 38].”
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer
Öhlund, D., Handly-Santana, A., Biffi, G., Elyada, E., Almeida, A. S., Ponz-Sarvise, M., Corbo, V., Oni, T. E., Hearn, S. A., Lee, E. J., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162024 · Cited by 2,590
Puram, S. V., Tirosh, I., Parikh, A. S., Patel, A. P., Yizhak, K., Gillespie, S., Rodman, C., Luo, C. L., Mroz, E. A., Emerick, K. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.044 · Cited by 2,557
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
Elyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
TRANSFORMING GROWTH FACTOR-β REGULATION OF IMMUNE RESPONSES
Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A.-K. L., & Flavell, R. A. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090737 · Cited by 2,206
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Similarly, an enzymatic depletion of hyaluronic acid using a clinically recombinant PH20 hyaluronidase (PEGPH20) facilitates the intra-tumoral penetration of standard chemotherapeutic agents [281, 282].”
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100 · cited 5×
“Many findings emerged from murine models of cancer, showed that targeting of specific signaling molecules in CAFs resulted in reduction of tumor growth, accompanied by a shift in the T cell response[20, 167-174].”
InfluentialStromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
Turning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705 · cited 10×
“Indeed, several CAF subpopulations have been identified and have either tumor-promoting [25, 27, 31-36] or tumor-suppressive effects [37, 38].”
InfluentialStromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
Phenotype molding of stromal cells in the lung tumor microenvironment
Lambrechts, D., Wauters, E., Boeckx, B., Aibar, S., Nittner, D., Burton, O., Bassez, A., Decaluwé, H., Pircher, A., Van den Eynde, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0096-5 · Cited by 1,648
Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Erez, N., Truitt, M., Olson, P., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.041 · Cited by 1,515
Calvo, F., Ege, N., Grande-Garcia, A., Hooper, S., Jenkins, R. P., Chaudhry, S. I., Harrington, K., Williamson, P., Moeendarbary, E., Charras, G., et al. (2013) · Nature Cell Biology · doi:10.1038/ncb2756 · Cited by 1,478
The reverse Warburg effect: Aerobic glycolysis in cancer associated fibroblasts and the tumor stroma
Pavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A. K., Frank, P. G., Casimiro, M. C., Wang, C., Fortina, P., Addya, S., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.23.10238 · Cited by 1,391
Biffi, G., Oni, T. E., Spielman, B., Hao, Y., Elyada, E., Park, Y., Preall, J., & Tuveson, D. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0710 · Cited by 1,360
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Su, S., Chen, J., Yao, H., Liu, J., Yu, S., Lao, L., Wang, M., Luo, M., Xing, Y., Chen, F., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.009 · Cited by 1,230
André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T., Bléry, M., Bonnafous, C., Gauthier, L., Morel, A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.014 · Cited by 1,221
Prostaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158
Salmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer
Jacobetz, M. A., Chan, D. S., Neesse, A., Bapiro, T. E., Cook, N., Frese, K. K., Feig, C., Nakagawa, T., Caldwell, M. E., Zecchini, H. I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-302529 · Cited by 1,120
Li, H., Courtois, E. T., Sengupta, D., Tan, Y., Chen, K. H., Goh, J. J. L., Kong, S. L., Chua, C., Hon, L. K., Tan, W. S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3818 · Cited by 1,080
Identification and characterization of a fibroblast marker: FSP1.
Strutz, F., Okada, H., Lo, C. W., Danoff, T., Carone, R. L., Tomaszewski, J. E., & Neilson, E. G. (1995) · The Journal of cell biology · doi:10.1083/jcb.130.2.393 · Cited by 1,077
Apoptosis of T cells mediated by galectin-1
Perillo, N. L., Pace, K. E., Seilhamer, J. J., & Baum, L. G. (1995) · Nature · doi:10.1038/378736a0 · Cited by 1,074
Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
Calon, A., Lonardo, E., Berenguer-Llergo, A., Espinet, E., Hernando-Momblona, X., Iglesias, M., Sevillano, M., Palomo-Ponce, S., Tauriello, D. V. F., Byrom, D., et al. (2015) · Nature Genetics · doi:10.1038/ng.3225 · Cited by 1,070
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060
Acerbi, I., Cassereau, L., Dean, I., Shi, Q., Au, A., Park, C., Chen, Y. Y., Liphardt, J., Hwang, E. S., & Weaver, V. M. (2015) · Integrative Biology · doi:10.1039/c5ib00040h · Cited by 1,059
Quante, M., Tu, S. P., Tomita, H., Gonda, T., Wang, S. S. W., Takashi, S., Baik, G. H., Shibata, W., DiPrete, B., Betz, K. S., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.020 · Cited by 1,044
Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 1×
“In this sense, the angiotensin inhibitor losartan, reduces stromal collagen and hyaluronan production and decreases the expression of profibrotic signals (TGF b 1, CCN2) [280].”
T cell apoptosis by tryptophan catabolism
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2002) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401073 · Cited by 1,022
Discovery of Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated Fibroblasts
Zeisberg, E. M., Potenta, S., Xie, L., Zeisberg, M., & Kalluri, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-3127 · Cited by 1,011
Targeting TGF-β Signaling in Cancer
Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003
Chen, P.-L., Roh, W., Reuben, A., Cooper, Z. A., Spencer, C. N., Prieto, P. A., Miller, J. P., Bassett, R. L., Gopalakrishnan, V., Wani, K., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1545 · Cited by 988
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
The impact of the extracellular matrix on inflammation
Sorokin, L. (2010) · Nature Reviews Immunology · doi:10.1038/nri2852 · Cited by 912
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.
Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910
Self-citationTurning 'sweet' on immunity: galectin–glycan interactions in immune tolerance and inflammation
Rabinovich, G. A., & Toscano, M. A. (2009) · Nature Reviews Immunology · doi:10.1038/nri2536 · Cited by 904
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Liu, T., Han, C., Wang, S., Fang, P., Ma, Z., Xu, L., & Yin, R. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0770-1 · Cited by 860 · cited 1×
“In addition, the recent characterization of CAFs, including identification of new CAFs subsets and their functional diversities, brings CAF-targeting therapies as promising tools for cancer treatment (Figure 3) [95, 106, 239].”
Dominguez, C. X., Müller, S., Keerthivasan, S., Koeppen, H., Hung, J., Gierke, S., Breart, B., Foreman, O., Bainbridge, T. W., Castiglioni, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0644 · Cited by 857
TGF-β Activation and Function in Immunity
Travis, M. A., & Sheppard, D. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120257 · Cited by 856
Is there new hope for therapeutic matrix metalloproteinase inhibition?
Vandenbroucke, R. E., & Libert, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4390 · Cited by 832
Bartoschek, M., Oskolkov, N., Bocci, M., Lövrot, J., Larsson, C., Sommarin, M., Madsen, C. D., Lindgren, D., Pekar, G., Karlsson, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07582-3 · Cited by 826
Yang, X., Lin, Y., Shi, Y., Li, B., Liu, W., Yin, W., Dang, Y., Chu, Y., Fan, J., & He, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2973 · Cited by 748
Labernadie, A., Kato, T., Brugués, A., Serra-Picamal, X., Derzsi, S., Arwert, E., Weston, A., González-Tarragó, V., Elosegui-Artola, A., Albertazzi, L., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3478 · Cited by 747
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0730640100 · Cited by 726
Goetz, J. G., Minguet, S., Navarro-Lérida, I., Lazcano, J. J., Samaniego, R., Calvo, E., Tello, M., Osteso-Ibáñez, T., Pellinen, T., Echarri, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.040 · Cited by 720
Identification of fibroblast heterogeneity in the tumor microenvironment
Sugimoto, H., Mundel, T. M., Kieran, M. W., & Kalluri, R. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.12.3354 · Cited by 699
De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
Yu, Y., Xiao, C.-H., Tan, L.-D., Wang, Q.-S., Li, X.-Q., & Feng, Y.-M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.768 · Cited by 676
Monteran, L., & Erez, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01835 · Cited by 675
Wang, L.-C. S., Lo, A., Scholler, J., Sun, J., Majumdar, R. S., Kapoor, V., Antzis, M., Cotner, C. E., Johnson, L. A., Durham, A. C., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0027 · Cited by 653
Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes
Winer, A., Adams, S., & Mignatti, P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0646 · Cited by 651
Fiori, M. E., Di Franco, S., Villanova, L., Bianca, P., Stassi, G., & De Maria, R. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0994-2 · Cited by 647
Loeffler, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26532 · Cited by 633 · cited 1×
“Similarly, conditional depletion of FAP + stromal cells in a mouse model of pancreatic cancer re-sensitizes cancer cells to anti-PD-1 and anti-CTLA-4 immunotherapies [241].”
Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
Sanjabi, S., Oh, S. A., & Li, M. O. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022236 · Cited by 621
Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590
Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity
Shalapour, S., Lin, X.-J., Bastian, I. N., Brain, J., Burt, A. D., Aksenov, A. A., Vrbanac, A. F., Li, W., Perkins, A., Matsutani, T., et al. (2017) · Nature · doi:10.1038/nature24302 · Cited by 589
Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., & Rettig, W. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.51.36505 · Cited by 586
Ene–Obong, A., Clear, A. J., Watt, J., Wang, J., Fatah, R., Riches, J. C., Marshall, J. F., Chin–Aleong, J., Chelala, C., Gribben, J. G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.025 · Cited by 579
Fiaschi, T., Marini, A., Giannoni, E., Taddei, M. L., Gandellini, P., De Donatis, A., Lanciotti, M., Serni, S., Cirri, P., & Chiarugi, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1949 · Cited by 578
Neutrophils in the tumor microenvironment
Powell, D. R., & Huttenlocher, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2015.11.008 · Cited by 578 · cited 1×
“N1 neutrophils show an anti-tumor phenotype with their capability of efficiently killing microorganisms and tumor cells, while N2 neutrophils exhibit a pro-tumor phenotype [195, 196].”
Lakins, M. A., Ghorani, E., Munir, H., Martins, C. P., & Shields, J. D. (2018) · Nature Communications · doi:10.1038/s41467-018-03347-0 · Cited by 578
Prostaglandin E2 Induces FOXP3 Gene Expression and T Regulatory Cell Function in Human CD4+ T Cells
Baratelli, F., Lin, Y., Zhu, L., Yang, S.-C., Heuzé-Vourc’h, N., Zeng, G., Reckamp, K., Dohadwala, M., Sharma, S., & Dubinett, S. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.3.1483 · Cited by 573
Erdogan, B., & Webb, D. J. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160387 · Cited by 558
Lahn, M., Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., Cleverly, A. L., Desaiah, D., Guba, S. C., et al. (2015) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86621 · Cited by 554
The role of endothelial-to-mesenchymal transition in cancer progression
Potenta, S., Zeisberg, E., & Kalluri, R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604662 · Cited by 554
Bochet, L., Lehuédé, C., Dauvillier, S., Wang, Y. Y., Dirat, B., Laurent, V., Dray, C., Guiet, R., Maridonneau-Parini, I., Le Gonidec, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0530 · Cited by 529
Comito, G., Giannoni, E., Segura, C. P., Barcellos-de-Souza, P., Raspollini, M. R., Baroni, G., Lanciotti, M., Serni, S., & Chiarugi, P. (2014) · Oncogene · doi:10.1038/onc.2013.191 · Cited by 528
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Galectin-3 and Galectin-1 Bind Distinct Cell Surface Glycoprotein Receptors to Induce T Cell Death
Stillman, B. N., Hsu, D. K., Pang, M., Brewer, C. F., Johnson, P., Liu, F.-T., & Baum, L. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.778 · Cited by 507
Sharma, S., Yang, S.-C., Zhu, L., Reckamp, K., Gardner, B., Baratelli, F., Huang, M., Batra, R. K., & Dubinett, S. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0141 · Cited by 506
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis
Ruhland, M. K., Loza, A. J., Capietto, A.-H., Luo, X., Knolhoff, B. L., Flanagan, K. C., Belt, B. A., Alspach, E., Leahy, K., Luo, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11762 · Cited by 496
Prima, V., Kaliberova, L. N., Kaliberov, S., Curiel, D. T., & Kusmartsev, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612920114 · Cited by 494
Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 494
Nissen, N. I., Karsdal, M., & Willumsen, N. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1110-6 · Cited by 489
Prostaglandin E2 differentially modulates cytokine secretion profiles of human T helper lymphocytes
Snijdewint, F. G., Kaliński, P., Wierenga, E. A., Bos, J. D., & Kapsenberg, M. L. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.12.5321 · Cited by 477
Neutrophils in cancer: prognostic role and therapeutic strategies
Ocana, A., Nieto-Jiménez, C., Pandiella, A., & Templeton, A. J. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0707-7 · Cited by 459
Pietras, K., Pahler, J., Bergers, G., & Hanahan, D. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050019 · Cited by 453
Laouar, Y., Sutterwala, F. S., Gorelik, L., & Flavell, R. A. (2005) · Nature Immunology · doi:10.1038/ni1197 · Cited by 451
Hong, D., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., Zhou, T., Schmidt, J., Jo, M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5272 · Cited by 445 · cited 1×
“…pathway already received FDA approval for the treatment of inflammatory pathologies and myeloproliferative neoplasms, and their efficacy was also approved in patients with hematopoietic malignancies and solid tumors, as they reduce tumor growth and increase sensitivity to chemotherapies [263, 264].”
The tumor microenvironment is a dominant force in multidrug resistance
Correia, A. L., & Bissell, M. J. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.006 · Cited by 443
Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis
Nielsen, S. R., Quaranta, V., Linford, A., Emeagi, P., Rainer, C., Santos, A., Ireland, L., Sakai, T., Sakai, K., Kim, Y.-S., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3340 · Cited by 441 · cited 1×
“Disruption of macrophages recruitment, or genetic depletion of granulin reduced CAFs activation and prevented liver metastasis [77, 78].”
Scott, A. M., Wiseman, G., Welt, S., Adjei, A. A., Lee, F.-T., Hopkins, W., Divgi, C. R., Hanson, L. J., Mitchell, P., Gansen, D. N., et al. (2003) · PubMed · Cited by 438
Liao, D., Luo, Y., Markowitz, D., Xiang, R., & Reisfeld, R. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007965 · Cited by 437 · cited 2×
“Many findings emerged from murine models of cancer, showed that targeting of specific signaling molecules in CAFs resulted in reduction of tumor growth, accompanied by a shift in the T cell response[20, 167-174].”
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C., & Östman, A. (2002) · PubMed · Cited by 433
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Santos, A. M., Jung, J., Aziz, N., Kissil, J. L., & Puré, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38988 · Cited by 428
Froeling, F. E. M., Feig, C., Chelala, C., Dobson, R., Mein, C. E., Tuveson, D. A., Clevers, H., Hart, I. R., & Kocher, H. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.047 · Cited by 418
Kaur, A., Ecker, B. L., Douglass, S. M., Kugel, C. H., Webster, M. R., Almeida, F. V., Somasundaram, R., Hayden, J., Ban, E., Ahmadzadeh, H., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0193 · Cited by 418
Pericyte–fibroblast transition promotes tumor growth and metastasis
Hosaka, K., Yang, Y., Seki, T., Fischer, C., Dubey, O., Fredlund, E., Hartman, J., Religa, P., Morikawa, H., Ishii, Y., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608384113 · Cited by 415
Roberts, E. W., Deonarine, A., Jones, J. O., Denton, A. E., Feig, C., Lyons, S. K., Espeli, M., Kraman, M., McKenna, B., Wells, R. J. B., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122344 · Cited by 414
Ford, K., Hanley, C. J., Mellone, M., Szyndralewiez, C., Heitz, F., Wiesel, P., Wood, O., Machado, M., Lopez, M.-A., Ganesan, A.-P., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3158 · Cited by 411
Chen, I. X., Chauhan, V. P., Posada, J., Ng, M. R., Wu, M. W., Adstamongkonkul, P., Huang, P., Lindeman, N., Langer, R., & Jain, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815515116 · Cited by 406
Cheng, Y., Li, H., Deng, Y., Tai, Y., Zeng, K., Zhang, Y., Liu, W., Zhang, Q., & Yang, Y. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0458-4 · Cited by 399
Tumor-Stroma Mechanics Coordinate Amino Acid Availability to Sustain Tumor Growth and Malignancy
Bertero, T., Oldham, W. M., Grasset, E. M., Bourget, I., Boulter, E., Pisano, S., Hofman, P., Bellvert, F., Meneguzzi, G., Bulavin, D. V., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.012 · Cited by 393
A2AR Adenosine Signaling Suppresses Natural Killer Cell Maturation in the Tumor Microenvironment
Young, A., Ngiow, S. F., Gao, Y., Patch, A.-M., Barkauskas, D. S., Messaoudene, M., Lin, G., Coudert, J. D., Stannard, K. A., Zitvogel, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2826 · Cited by 391
Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics
Puré, E., & Blomberg, R. (2018) · Oncogene · doi:10.1038/s41388-018-0275-3 · Cited by 391
Pelon, F., Bourachot, B., Kieffer, Y., Magagna, I., Mermet-Meillon, F., Bonnet, I., Costa, A., Givel, A.-M., Attieh, Y., Barbazan, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14134-w · Cited by 390
Self-citationAlteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts
Ziani, L., Chouaib, S., & Thiery, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00414 · Cited by 381
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
Kidd, S., Spaeth, E., Watson, K., Burks, J., Lu, H., Klopp, A., Andreeff, M., & Marini, F. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030563 · Cited by 371
Albrengues, J., Bertero, T., Grasset, E., Bonan, S., Maiel, M., Bourget, I., Philippe, C., Herraiz Serrano, C., Benamar, S., Croce, O., et al. (2015) · Nature Communications · doi:10.1038/ncomms10204 · Cited by 367
Wu, X., Tao, P., Zhou, Q., Li, J., Yu, Z., Wang, X., Li, J., Li, C., Yan, M., Zhu, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15119 · Cited by 367
Kato, T., Noma, K., Ohara, T., Kashima, H., Katsura, Y., Sato, H., Komoto, S., Katsube, R., Ninomiya, T., Tazawa, H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0205 · Cited by 367
Glentis, A., Oertle, P., Mariani, P., Chikina, A., El Marjou, F., Attieh, Y., Zaccarini, F., Lae, M., Loew, D., Dingli, F., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00985-8 · Cited by 363
Chang, S.-H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., Lane, T. F., & Hla, T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2535911100 · Cited by 361
VEGF-A and Tenascin-C produced by S100A4 + stromal cells are important for metastatic colonization
O'Connell, J. T., Sugimoto, H., Cooke, V. G., MacDonald, B. A., Mehta, A. I., LeBleu, V. S., Dewar, R., Rocha, R. M., Brentani, R. R., Resnick, M. B., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109493108 · Cited by 348
Zhang, R., Qi, F., Zhao, F., Li, G., Shao, S., Zhang, X., Yuan, L., & Feng, Y. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1435-2 · Cited by 343
TGF-beta in CAF-mediated tumor growth and metastasis
Calon, A., Tauriello, D. V. F., & Batlle, E. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.008 · Cited by 342
Oxidative stress promotes myofibroblast differentiation and tumour spreading
Toullec, A., Gerald, D., Despouy, G., Bourachot, B., Cardon, M., Lefort, S., Richardson, M., Rigaill, G., Parrini, M., Lucchesi, C., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000073 · Cited by 339
Self-citationCancer-associated fibroblasts lead tumor invasion through integrin-β3–dependent fibronectin assembly
Attieh, Y., Clark, A. G., Grass, C., Richon, S., Pocard, M., Mariani, P., Elkhatib, N., Betz, T., Gurchenkov, B., & Vignjevic, D. M. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201702033 · Cited by 338
Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic Carcinogenesis
Mizutani, Y., Kobayashi, H., Iida, T., Asai, N., Masamune, A., Hara, A., Esaki, N., Ushida, K., Mii, S., Shiraki, Y., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0454 · Cited by 336
Hingorani, S. R., Harris, W. P., Beck, J. T., Berdov, B. A., Wagner, S. A., Pshevlotsky, E. M., Tjulandin, S. A., Gladkov, O. A., Holcombe, R. F., Korn, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2010 · Cited by 333
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity
Balsamo, M., Scordamaglia, F., Pietra, G., Manzini, C., Cantoni, C., Boitano, M., Queirolo, P., Vermi, W., Facchetti, F., Moretta, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906481106 · Cited by 330
Heichler, C., Scheibe, K., Schmied, A., Geppert, C. I., Schmid, B., Wirtz, S., Thoma, O.-M., Kramer, V., Waldner, M. J., Büttner, C., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319200 · Cited by 328
The role of reactive oxygen species and metabolism on cancer cells and their microenvironment
Costa, A., Scholer-Dahirel, A., & Mechta-Grigoriou, F. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.007 · Cited by 324
Self-citationMechanotransduction in tumor progression: The dark side of the force
Broders-Bondon, F., Nguyen Ho-Bouldoires, T. H., Fernandez-Sanchez, M.-E., & Farge, E. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201701039 · Cited by 319
CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer
Pereira, B. A., Vennin, C., Papanicolaou, M., Chambers, C. R., Herrmann, D., Morton, J. P., Cox, T. R., & Timpson, P. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.09.010 · Cited by 314
Khalili, J. S., Liu, S., Rodríguez-Cruz, T. G., Whittington, M., Wardell, S., Liu, C., Zhang, M., Cooper, Z. A., Frederick, D. T., Li, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1632 · Cited by 301
miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers
Givel, A.-M., Kieffer, Y., Scholer-Dahirel, A., Sirven, P., Cardon, M., Pelon, F., Magagna, I., Gentric, G., Costa, A., Bonneau, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03348-z · Cited by 295
Neuzillet, C., Tijeras‐Raballand, A., Ragulan, C., Cros, J., Patil, Y., Martinet, M., Erkan, M., Kleeff, J., Wilson, J., Apte, M., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5224 · Cited by 295
Gok Yavuz, B., Gunaydin, G., Gedik, M. E., Kosemehmetoglu, K., Karakoc, D., Ozgur, F., & Guc, D. (2019) · Scientific Reports · doi:10.1038/s41598-019-39553-z · Cited by 292
Cohen, N., Shani, O., Raz, Y., Sharon, Y., Hoffman, D., Abramovitz, L., & Erez, N. (2017) · Oncogene · doi:10.1038/onc.2017.65 · Cited by 292
Becker, L. M., O’Connell, J. T., Vo, A. P., Cain, M. P., Tampe, D., Bizarro, L., Sugimoto, H., McGow, A. K., Asara, J. M., Lovisa, S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107701 · Cited by 291
Kim, D. J., Kim, J., Spaunhurst, K., Montoya, J., Khodosh, R., Chandra, K., Fu, T., Gilliam, A., Molgo, M., Beachy, P. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9525 · Cited by 289
Horvath, L., Thienpont, B., Zhao, L., Wolf, D., & Pircher, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01260-z · Cited by 283
Trotta, R., Col, J. D., Yu, J., Ciarlariello, D., Thomas, B., Zhang, X., Allard, J., Wei, M., Mao, H., Byrd, J. C., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3784 · Cited by 275
Brandes, A. A., Carpentier, A. F., Kesari, S., Sepulveda-Sanchez, J. M., Wheeler, H. R., Chinot, O., Cher, L., Steinbach, J. P., Capper, D., Specenier, P., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now009 · Cited by 273
Claus, C., Ferrara, C., Xu, W., Sam, J., Lang, S., Uhlenbrock, F., Albrecht, R., Herter, S., Schlenker, R., Hüsser, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5989 · Cited by 270
Regulation of the anti-tumour immune response by cancer-associated fibroblasts
Harper, J., & Sainson, R. C. A. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.005 · Cited by 268
Bone marrow–derived fibroblasts are a functionally distinct stromal cell population in breast cancer
Raz, Y., Cohen, N., Shani, O., Bell, R. E., Novitskiy, S. V., Abramovitz, L., Levy, C., Milyavsky, M., Leider-Trejo, L., Moses, H. L., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180818 · Cited by 268
Cheng, J.-T., Deng, Y.-N., Yi, H.-M., Wang, G.-Y., Fu, B.-S., Chen, W.-J., Liu, W., Tai, Y., Peng, Y.-W., & Zhang, Q. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.7 · Cited by 267
Welt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., & Old, L. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.6.1193 · Cited by 266
Ham, I.-H., Oh, H. J., Jin, H., Bae, C. A., Jeon, S.-M., Choi, K. S., Son, S.-Y., Han, S.-U., Brekken, R. A., Lee, D., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0972-8 · Cited by 264
Tinoco, R., Alcalde, V., Yang, Y., Sauer, K., & Zuniga, E. I. (2009) · Immunity · doi:10.1016/j.immuni.2009.06.015 · Cited by 261
Nazareth, M. R., Broderick, L., Simpson-Abelson, M. R., Kelleher, R. J., Yokota, S. J., & Bankert, R. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5552 · Cited by 259
Takahashi, H., Sakakura, K., Kudo, T., Toyoda, M., Kaira, K., Oyama, T., & Chikamatsu, K. (2017) · Oncotarget · doi:10.18632/oncotarget.14374 · Cited by 259
Xiang, H., Ramil, C. P., Hai, J., Zhang, C., Wang, H., Watkins, A. A., Afshar, R., Georgiev, P., Sze, M. A., Song, X. S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0507 · Cited by 256
Zhuang, J., Lu, Q., Shen, B., Huang, X., Shen, L., Zheng, X., Huang, R., Yan, J., & Guo, H. (2015) · Scientific Reports · doi:10.1038/srep11924 · Cited by 252
Kelley, R. K., Gane, E., Assenat, E., Siebler, J., Galle, P. R., Merle, P., Hourmand, I. O., Cleverly, A., Zhao, Y., Gueorguieva, I., et al. (2019) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000056 · Cited by 247
Lind, H., Gameiro, S. R., Jochems, C., Donahue, R. N., Strauss, J., Gulley, J. L., Palena, C., & Schlom, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000433 · Cited by 247
Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts
Ostermann, E., Garin-Chesa, P., Heider, K. H., Kalat, M., Lamche, H., Puri, C., Kerjaschki, D., Rettig, W. J., & Adolf, G. R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5211 · Cited by 246
Biophysics of tumor microenvironment and cancer metastasis – a mini review
Emon, B., Bauer, J., Jain, Y., Jung, B., & Saif, T. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.07.003 · Cited by 245
Comito, G., Iscaro, A., Bacci, M., Morandi, A., Ippolito, L., Parri, M., Montagnani, I., Raspollini, M. R., Serni, S., Simeoni, L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0688-7 · Cited by 241
Targeting natural killer cells in solid tumors
Habif, G., Crinier, A., André, P., Vivier, E., & Narni-Mancinelli, E. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0224-2 · Cited by 241
Heterogeneity in Cancer Metabolism: New Concepts in an Old Field
Gentric, G., Mieulet, V., & Mechta-Grigoriou, F. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6750 · Cited by 240
Self-citationPrevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer
Hartmann, N., Giese, N. A., Giese, T., Poschke, I., Offringa, R., Werner, J., & Ryschich, E. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2972 · Cited by 230
Miyake, M., Hori, S., Morizawa, Y., Tatsumi, Y., Nakai, Y., Anai, S., Torimoto, K., Aoki, K., Tanaka, N., Shimada, K., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.002 · Cited by 228
Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., Lin, C., Pan, Z., Yu, Y., Jiang, M., et al. (2014) · Hepatology · doi:10.1002/hep.26694 · Cited by 226
Ahmadzadeh, M., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5215 · Cited by 225
Combined CSL and p53 downregulation promotes cancer-associated fibroblast activation
Procopio, M.-G., Laszlo, C., Al Labban, D., Kim, D. E., Bordignon, P., Jo, S.-H., Goruppi, S., Menietti, E., Ostano, P., Ala, U., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3228 · Cited by 223
TGF-β–inducible microRNA-183 silences tumor-associated natural killer cells
Donatelli, S. S., Zhou, J.-M., Gilvary, D. L., Eksioglu, E. A., Chen, X., Cress, W. D., Haura, E. B., Schabath, M. B., Coppola, D., Wei, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1319269111 · Cited by 221
Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D. A., & Kang, Y. (2009) · Nature Medicine · doi:10.1038/nm.1943 · Cited by 217
Zhang, A., Qian, Y., Ye, Z., Chen, H., Xie, H., Zhou, L., Shen, Y., & Zheng, S. (2017) · Cancer Medicine · doi:10.1002/cam4.993 · Cited by 216
Duluc, C., Moatassim‐Billah, S., Chalabi‐Dchar, M., Perraud, A., Samain, R., Breibach, F., Gayral, M., Cordelier, P., Delisle, M., Bousquet‐Dubouch, M., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404346 · Cited by 214
LIF Mediates Proinvasive Activation of Stromal Fibroblasts in Cancer
Albrengues, J., Bourget, I., Pons, C., Butet, V., Hofman, P., Tartare-Deckert, S., Feral, C. C., Meneguzzi, G., & Gaggioli, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.036 · Cited by 212
Cremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K., Woodruff, M. C., Wu, M., Spel, L., Santoro, S., Amoozgar, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0098 · Cited by 207
Extracellular matrix directs phenotypic heterogeneity of activated fibroblasts
Avery, D., Govindaraju, P., Jacob, M., Todd, L., Monslow, J., & Puré, E. (2018) · Matrix Biology · doi:10.1016/j.matbio.2017.12.003 · Cited by 206
Elkabets, M., Gifford, A. M., Scheel, C., Nilsson, B., Reinhardt, F., Bray, M.-A., Carpenter, A. E., Jirström, K., Magnusson, K., Ebert, B. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43757 · Cited by 201 · cited 1×
“Disruption of macrophages recruitment, or genetic depletion of granulin reduced CAFs activation and prevented liver metastasis [77, 78].”
Laoui, D., Van Overmeire, E., De Baetselier, P., Van Ginderachter, J. A., & Raes, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00489 · Cited by 200
CAFs and TAMs: maestros of the tumour microenvironment
Komohara, Y., & Takeya, M. (2017) · The Journal of Pathology · doi:10.1002/path.4824 · Cited by 197
The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer
Sun, Q., Zhang, B., Hu, Q., Qin, Y., Xu, W., Liu, W., Yu, X., & Xu, J. (2018) · Theranostics · doi:10.7150/thno.26546 · Cited by 193
Gorchs, L., Fernández Moro, C., Bankhead, P., Kern, K. P., Sadeak, I., Meng, Q., Rangelova, E., & Kaipe, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00847 · Cited by 193
Kuen, J., Darowski, D., Kluge, T., & Majety, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0182039 · Cited by 192
Cancer‐associated fibroblasts promote PD‐L1 expression in mice cancer cells via secreting CXCL5
Li, Z., Zhou, J., Zhang, J., Li, S., Wang, H., & Du, J. (2019) · International Journal of Cancer · doi:10.1002/ijc.32278 · Cited by 192
Sanjabi, S., Mosaheb, M. M., & Flavell, R. A. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.020 · Cited by 190
Tumor‐stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7
Jung, D., Che, Z. M., Kim, J., Kim, K., Kim, K., Williams, D., & Kim, J. (2010) · International Journal of Cancer · doi:10.1002/ijc.25060 · Cited by 186
Dynamic Mast Cell–Stromal Cell Interactions Promote Growth of Pancreatic Cancer
Ma, Y., Hwang, R. F., Logsdon, C. D., & Ullrich, S. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4479 · Cited by 186
Deng, Y., Cheng, J., Fu, B., Liu, W., Chen, G., Zhang, Q., & Yang, Y. (2017) · Oncogene · doi:10.1038/onc.2016.273 · Cited by 186
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability
Morel, A.-P., Ginestier, C., Pommier, R. M., Cabaud, O., Ruiz, E., Wicinski, J., Devouassoux-Shisheboran, M., Combaret, V., Finetti, P., Chassot, C., et al. (2017) · Nature Medicine · doi:10.1038/nm.4323 · Cited by 186
Hyaluronan Deficiency in Tumor Stroma Impairs Macrophage Trafficking and Tumor Neovascularization
Kobayashi, N., Miyoshi, S., Mikami, T., Koyama, H., Kitazawa, M., Takeoka, M., Sano, K., Amano, J., Isogai, Z., Niida, S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4687 · Cited by 185
PD-1 Ligand Expression by Human Colonic Myofibroblasts/Fibroblasts Regulates CD4+ T-Cell Activity
Pinchuk, I. V., Saada, J. I., Beswick, E. J., Boya, G., Qiu, S. M., Mifflin, R. C., Raju, G. S., Reyes, V. E., & Powell, D. W. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.016 · Cited by 184
Fibroblast-specific inhibition of TGF-β1 signaling attenuates lung and tumor fibrosis
Wei, Y., Kim, T. J., Peng, D. H., Duan, D., Gibbons, D. L., Yamauchi, M., Jackson, J. R., Le Saux, C. J., Calhoun, C., Peters, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94624 · Cited by 184
Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01878 · Cited by 179
Yang, Z., Zhang, B., Li, D., Lv, M., Huang, C., Shen, G.-X., & Huang, B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008922 · Cited by 177
Sharon, Y., Raz, Y., Cohen, N., Ben-Shmuel, A., Schwartz, H., Geiger, T., & Erez, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1990 · Cited by 177
Li, P., Shan, J.-X., Chen, X.-H., Zhang, D., Su, L.-P., Huang, X.-Y., Yu, B.-Q., Zhi, Q.-M., Li, C.-L., Wang, Y.-Q., et al. (2015) · Cell Research · doi:10.1038/cr.2015.51 · Cited by 173
Cited by
Clinical and therapeutic relevance of cancer-associated fibroblasts
Chen, Y., McAndrews, K. M., & Kalluri, R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00546-5 · Cited by 1,230
Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer
Wu, F., Yang, J., Liu, J., Wang, Y., Mu, J., Zeng, Q., Deng, S., & Zhou, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00641-0 · Cited by 773
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Jenkins, L., Jungwirth, U., Avgustinova, A., Iravani, M., Mills, A., Haider, S., Harper, J., & Isacke, C. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4141 · Cited by 279
Hirz, T., Mei, S., Sarkar, H., Kfoury, Y., Wu, S., Verhoeven, B. M., Subtelny, A. O., Zlatev, D. V., Wszolek, M. W., Salari, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36325-2 · Cited by 277
Metadata
- Authors
- Mhaidly, R., & Mechta-Grigoriou, F.
- Venue
- Seminars in Immunology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 48
- Pages
- 101417
- ISSN
- 1044-5323 (ISSN-L)
- OpenAlex
- W3093192089
- Cited by
- 259
- References
- 288
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.